Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17 alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III

Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17 alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III

Author Silva, R. D. Google Scholar
Kater, Claudio Elias Autor UNIFESP Google Scholar
Dib, Sergio Atala Autor UNIFESP Google Scholar
Laureti, S. Google Scholar
Forini, F. Google Scholar
Cosentino, A. Google Scholar
Falorni, A. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Univ Perugia
Abstract Objective: To evaluate the frequency of autoantibodies (Ab) against 21 hydroxylase (210H), side-chain cleavage (SCC) and 17 alpha-hydroxglase (17OH), in Addison's disease (AD) and autoimmune polyendocrine syndrome type III (APSIII), Design and Methods: We used radiobinding assays and in vitro translated recombinant human S-35-21OH, S-35-SCC or S-35-17OH and studied serum samples from 29 AD (18 idiopathic, 11 granulomatous) and 18 APSIII (autoimmune thyroid disease plus type 1 diabetes mellitus, without AD) patients. Results were compared with those of adrenocortical autoantibodies obtained with indirect immunofluorescence (ACA-IIF). Results: ACA-IIF were detected in 15/18 (83%) idiopathic and in 1/11 (9%) granulomatous AD subjects. 21OHAb were found in 14/18 (78%) idiopathic and in the same (9%) granulomatous AD subject. A significant positive correlation was shown between ACA-IIF and 21OHAb levels (r(2) = 0.56, P < 0.02). The concordance rate between the two assays was 83% (24/29) in AD patients. SCCAb were found in 5/15 (28%) idiopathic (4 of whom were also positive for 21OHAb) and in the same (9%) granulomatous AD subject, 170HAb were found in only 2/18 (11%) idiopathic and none of the granulomatous AD patients. Two APSIII patients were positive for ACA-IIE but only one was positive for 210HAb and SCCAb. 170HAb were found in another two APSIII patients. Conclusions: Measurement of 210HAb should be the first step in immune assessment of patients with AD and individuals at risk for adrenal autoimmunity, in addition to ACA-IIF. Due to their low prevalence in AD, measurement of SCCAb and 170HAb should be indicated only for 210HAb negative patients and/or for those with premature ovarian failure, regardless of ACA-IIF results.
Language English
Date 2000-02-01
Published in European Journal Of Endocrinology. Oslo: Scandinavian University Press, v. 142, n. 2, p. 187-194, 2000.
ISSN 0804-4643 (Sherpa/Romeo, impact factor)
Publisher Scandinavian University Press
Extent 187-194
Origin https://doi.org/10.1530/eje.0.1420187
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000085405600015
URI http://repositorio.unifesp.br/11600/43587

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account